China Structural Reform Fund is a state-owned private equity fund.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
China Structural Reform Fund aims to provide state-owned enterprises support in development, industrial consolidation, professional reorganization, capacity adjustment and international mergers and acquisitions by establishing sub-fund as well as direct investment.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
12/2019 | Teld New Energy | Venture Round | 193.6M |
1/2018 | ADAMA Agricultural Solutions | Post-IPO Equity | 0 |
10/2020 | Zhenkunxing | Series E | 315M |
1/2023 | China Resources Pharmaceutical Group | Series B | 88.5M |
6/2020 | Qiniu | Series F | 141.1M |
8/2022 | Cygnus Biosciences | Series C | 29.6M |
3/2020 | Teld New Energy | Series A | 194.6M |
8/2021 | MetaX | Series A | 154.5M |
10/2020 | Zhenkunhang | Series E | 0 |
5/2021 | WeRide | Series C | 0 |
12/2017 | WM Motor | Corporate Round | - |
3/2022 | Tianxinhe Biotech | Venture Round | - |
10/2022 | GAC Aion New Energy Automobile | Series A | 0 |
10/2020 | GeneCast Biotechnology | Series E | - |
11/2021 | GTA Semiconductor | Venture Round | 0 |
1/2023 | Xiaodu | Series B | - |
2/2018 | JD Logistics | Venture Round | 2.5B |
5/2022 | Xuelangyun | Series B | 0 |
4/2020 | COSMOplat | Series A | 0 |
1/2020 | Teld New Energy | Series A | 0 |
7/2021 | TransThera Biosciences | Series D | 100M |
7/2019 | Ouyeel | Series B | 291.9M |
5/2022 | Xuelangyun | Series B | 0 |
3/2022 | Tianxinhe Biotech | Venture Round | - |
11/2021 | GTA Semiconductor | Venture Round | 0 |
8/2021 | MetaX | Series A | 0 |
7/2021 | TransThera Biosciences | Series D | 0 |
5/2021 | WeRide | Series C | 0 |
10/2020 | Zhenkunxing | Series E | 0 |
10/2020 | Zhenkunhang | Series E | 0 |
10/2020 | GeneCast Biotechnology | Series E | - |
6/2020 | Qiniu | Series F | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|